Key facts
- Vaxxas’s last known valuation is $235.6M (Aug 2025).
- It has raised $154.3M; the latest was Later Stage VC ($58.0M) in Aug 2025.
- Notable investors include Gates Foundation, QIC, Wellcome Trust, Brandon Capital, SPRIM Global Investments — 22 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for Vaxxas
- ·The full record, as it builds
Funding rounds
No funding rounds for Vaxxas are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vaxxas
Developer of a needle-free vaccine delivery system designed to enhance the performance of existing and next-generation vaccines. The company's system consists of an array of vaccine-coated microprojections that perforate the outer layers of the skin when applied with an applicator device, enabling medical practitioners to directly deposit vaccine amongst a dense population of immune cells in the skin.
- Sector
- Healthcare
- HQ
- Hamilton, Australia
- Founded
- 2011
- Employees
- 129
- Website
- vaxxas.com/
- Ownership
- Privately Held (backing)
Vaxxas doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vaxxas shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vaxxas in its N-PORT filings yet. We sweep new filings monthly.